Man-Yee Chan

Title: Man-Yee Chan: Innovator in Cancer Risk Assessment

Introduction

Man-Yee Chan is a notable inventor based in Taichung, Taiwan. She has made significant contributions to the field of cancer research, particularly in the assessment of oral cancer risk. Her innovative work has the potential to impact the way we detect and understand cancer-related diseases.

Latest Patents

Man-Yee Chan holds a patent for a peptide, antibody thereof, and method of assessing the risk of oral cancer by using the peptide. The patent discloses a THLW peptide, with an amino acid sequence represented by SEQ ID No. 1. This THLW peptide serves as a biomarker for diseases such as oral cancer and cervical cancer, which are associated with human papilloma virus (HPV) infection. The peptide can be utilized as an antigen or in the preparation of an anti-THLW peptide antibody, aiding in the detection of cancer risk for individuals.

Career Highlights

Throughout her career, Man-Yee Chan has worked with esteemed institutions, including Tungchai University and Taichung Veterans General Hospital. Her roles in these organizations have allowed her to advance her research and contribute to the scientific community.

Collaborations

Man-Yee Chan has collaborated with notable colleagues, including Feng-Di Lung and Ye-song Gu. These partnerships have fostered a collaborative environment that enhances research outcomes and innovation.

Conclusion

Man-Yee Chan's work in cancer risk assessment through innovative peptide research exemplifies the importance of scientific advancements in healthcare. Her contributions are paving the way for improved detection methods and better understanding of cancer risks.